Concepedia

Lauretta Odogwu

LO

5

Publications

618

Citations

5

H-Index

2004

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Lauretta Odogwu is an author at United States Food and Drug Administration specializing in oncology, medicine, and cancer research.

Top concepts

Publications per year

2004–2018

5

Publications

5

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

John L. Marshall, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2004 · 296 citations

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> Mutations

Lauretta Odogwu, Luckson Mathieu, Gideon M. Blumenthal et al. · The Oncologist · 2018 · 212 citations · Full text

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Lauretta Odogwu, Luckson Mathieu, Kirsten B. Goldberg et al. · The Oncologist · 2017 · 61 citations · Full text

A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

N. Fernando, Daohai Yu, Michael A. Morse et al. · Journal of Clinical Oncology · 2005 · 37 citations

, , +12

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

Philip Bonomi, Gideon M. Blumenthal, Andrea Stern Ferris et al. · Journal of Thoracic Oncology · 2018 · 12 citations

, , +10

Rows per page

1–5 of 5